Search results
Showing 241 to 255 of 661 results for diabetes
effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes? Any explanatory notes(if applicable) For a...
This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS52Show all sections
Sections for QS52
- Quality statements
- Quality statement 1: Identification and assessment of peripheral arterial disease
- Quality statement 2: Comorbidity assessment
- Quality statement 3: Supervised exercise programmes
- Quality statement 4: Imaging
- Quality statement 5: Angioplasty for intermittent claudication
- About this quality standard
Familial hypercholesterolaemia: identification and management (CG71)
This guideline covers identifying and managing familial hypercholesterolaemia (FH), a specific type of high cholesterol that runs in the family, in children, young people and adults. It aims to help identify people at increased risk of coronary heart disease as a result of having FH.
This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support.
Psychosis and schizophrenia in children and young people: recognition and management (CG155)
This guideline covers recognising and managing psychosis and schizophrenia in children and young people. It aims to improve early recognition of psychosis and schizophrenia so that children and young people can be offered the treatment and care they need to live with the condition.
Kidney conditions: CKD urine albumin:creatinine ratio (IND144)
This indicator covers the percentage of patients on the CKD register whose notes have a record of a urine albumin:creatinine ratio (or protein:creatinine ratio) test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM109
Bipolar, schizophrenia and other psychoses: target organ damage (IND86)
This indicator covers the percentage of patients on lithium therapy with a record of serum creatinine and TSH in the preceding 9 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM21
Laparoscopic gastric plication for the treatment of severe obesity (HTG293)
Evidence-based recommendations on laparoscopic gastric plication for the treatment of morbid obesity. This involves folding the stomach in on itself and stitching it together to reduce its volume.
View recommendations for HTG293Show all sections
Sections for HTG293
NG19/2 Question When and with what criteria should people with diabetes be referred to the foot protection service or the...
NG19/2 Question When and with what criteria should people with diabetes be referred to the foot protection service or the...
'total population' or 'high-risk population' approach to preventing type 2 diabetes among people from black and minority ethnic or lower...
Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
In development Reference number: GID-TA11793 Expected publication date: 18 November 2026
This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72
In development Reference number: GID-HST10067 Expected publication date: 19 August 2026